Skip to main content

Cycle to Amsterdam

Posted: Mon 25 Mar 2013

London to Amsterdam ride

Image by:

Blues are backing the Football League's London to Amsterdam Challenge in support of Prostate Cancer UK, the Football League's official charity partner.

The challenge will see fans, players and club officials from across The Football League take to the saddle for a unique two day 'Total Football' themed, 155 mile challenge from London to Amsterdam, for the 250,000 men living with prostate cancer across the UK.

Kicking off on Friday 14 June, the route will pass through the picturesque countryside of rural England, before crossing The Channel at Harwich and onto the flat landscape of Dutch Zeeland. The sight of Amsterdam with its network of canals, cobbled streets and wonderful architecture on Saturday will mark the end of a fantastic ride and the start of the Total Football celebrations.

Former England, Watford and AC Milan Striker, Luther Blissett (pictured), has already signed up, and other footballing legends are expected to follow.  Luther said: “I am thrilled to be taking on the London to Amsterdam ride in support of Prostate Cancer UK and its Official Charity Partnership with The Football League. It will be a great experience as fans from across The League will join forces on their bikes to raise thousands of pounds to help the charity support the 250,000 UK men living with prostate cancer - that's enough to fill Wembley Stadium three times over."

Fans can find more details and sign up to represent Blues at in the London-Amsterdam cycling challenge. Prostate Cancer UK asks cyclists to raise a minimum of £1,000.  The registration fee is £149. Spaces are limited to 20 places per club.

Download the full brochure for the London to Amsterdam Challenge here.
London to Amsterdam ride2_16x9
While it is already the most common cancer in men, prostate cancer is predicted to become the most common cancer of all in the UK by 2030. It's as big an issue for men as breast cancer is for women — yet prostate cancer gets just a fraction of the money for research. The disease is poorly understood, the tests aren't good enough, and the treatments can have life-changing side effects.